^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2182 / 24 - The evolution of high grade serous ovarian cancer under the pressure of non-cytotoxic and cytotoxic treatment
Published date:
03/15/2023
Excerpt:
In the BRCA WT HRp study group, the greatest response was seen in the triplet Ola+BEV+ATz combinations and interestingly no significant differences were observed using a lower dose of BEV….The triplet combination of low-dose-intensity bevacizumab with other non-cytotoxic drugs was an effective regimen for BRCA WT syngeneic mouse tumors.
